文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Noonan综合征相关心肌病临床前模型中的内含子CRISPR修复

Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome-Associated Cardiomyopathy.
PubMed 文献 · Circulation · 2020-07-06

本研究基于携带LZTR1双等位基因突变的常染色体隐性Noonan综合征两姐妹,构建患者特异性iPSC来源心肌细胞,再现肥厚表型并揭示LZTR1功能缺陷与RAS-MAPK信号过度激活、肥厚基因反应及细胞肥大的因果联系;钙通道阻滞和MEK抑制可部分预防疾病特征,概念验证性内含子CRISPR修复可逆转肥厚表型。

要点

  • LZTR1双等位基因突变致常染色体隐性Noonan综合征伴重度肥厚型心肌病。
  • 患者iPSC来源心肌细胞再现肥厚表型,揭示LZTR1-RAS-MAPK-肥厚基因轴。
  • 内含子CRISPR修复在概念验证中逆转肥厚表型,具临床转化潜力。

核心结论

  • LZTR1双等位基因突变通过RAS-MAPK信号过度激活驱动Noonan综合征相关肥厚型心肌病。
  • 内含子CRISPR修复可作为个性化且具临床转化潜力的治疗策略。

研究设计与样本

  • 病例家系研究:两姐妹表现为常染色体隐性Noonan综合征伴重度肥厚型心肌病,携带LZTR1双等位基因突变。
  • 构建患者特异性iPSC来源心肌细胞,进行分子与功能水平研究。

主要发现

  • 患者iPSC来源心肌细胞再现肥厚表型。
  • 发现LZTR1功能障碍、RAS-MAPK信号过度激活、肥厚基因反应与细胞肥大之间的因果联系。
  • 钙通道阻滞和MEK抑制可预防部分疾病特征,但可能非可持续治疗选择。
  • 概念验证性内含子CRISPR修复可逆转肥厚表型。
  • 鉴定出疾病特异性蛋白质组特征。

临床怎么用

  • 钙通道阻滞和MEK抑制可能对Noonan综合征患者有临床获益,但需权衡可持续性。
  • 内含子CRISPR修复作为个性化治疗策略,需进一步临床前验证。

局限性

  • 研究基于两姐妹的iPSC模型,样本量有限。
  • CRISPR修复仅为例概念验证,尚未在临床中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Noonan syndrome (NS) is a multisystemic developmental disorder characterized by common, clinically variable symptoms, such as typical facial dysmorphisms, short stature, developmental delay, intellectual disability as well as cardiac hypertrophy. The underlying mechanism is a gain-of-function of the RAS-mitogen-activated protein kinase signaling pathway. However, our understanding of the pathophysiological alterations and mechanisms, especially of the associated cardiomyopathy, remains limited and effective therapeutic options are lacking. METHODS: Here, we present a family with two siblings displaying an autosomal recessive form of NS with massive hypertrophic cardiomyopathy as clinically the most prevalent symptom caused by biallelic mutations within the leucine zipper-like transcription regulator 1 (LZTR1). We generated induced pluripotent stem cell-derived cardiomyocytes of the affected siblings and investigated the patient-specific cardiomyocytes on the molecular and functional level. RESULTS: Patients' induced pluripotent stem cell-derived cardiomyocytes recapitulated the hypertrophic phenotype and uncovered a so-far-not-described causal link between LZTR1 dysfunction, RAS-mitogen-activated protein kinase signaling hyperactivity, hypertrophic gene response and cellular hypertrophy. Calcium channel blockade and MEK inhibition could prevent some of the disease characteristics, providing a molecular underpinning for the clinical use of these drugs in patients with NS, but might not be a sustainable therapeutic option. In a proof-of-concept approach, we explored a clinically translatable intronic CRISPR (clustered regularly interspaced short palindromic repeats) repair and demonstrated a rescue of the hypertrophic phenotype. CONCLUSIONS: Our study revealed the human cardiac pathogenesis in patient-specific induced pluripotent stem cell-derived cardiomyocytes from NS patients carrying biallelic variants in LZTR1 and identified a unique disease-specific proteome signature. In addition, we identified the intronic CRISPR repair as a personalized and in our view clinically translatable therapeutic strategy to treat NS-associated hypertrophic cardiomyopathy.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Hanses U, Kleinsorge M, Roos L, et al. Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome-Associated Cardiomyopathy. Circulation. 2020. PMID: 32623905. doi:10.1161/CIRCULATIONAHA.119.044794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。